Thank you for your interest in contacting Medical Information at Johnson & Johnson. We look forward to addressing your medical information questions for products marketed in the United States. For international inquiries, we must refer you to our affiliates.
To submit a medical information question related to a Johnson & Johnson product or to report a side effect or product complaint, please reach out to Medical Information at Johnson & Johnson via options listed below.
You can also report a side effect or product complaint of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Phone:
Please call: 1-800-526-7736 Monday-Friday, 9 am - 8 pm ET.
Johnson & Johnson, Medical Information 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560
This site is intended for U.S. healthcare professionals
You are now leaving UptraviHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
1.4 YEARS (median duration of UPTRAVI*) Longest endpoint evaluation period of any prostacyclin pathway therapy
Baseline Patient Characteristics1,5
Mean age: 48 years
Female: 80%
Median time from PAH diagnosis in patients taking UPTRAVI®: 0.9 years
ETIOLOGY
IPAH/HPAH 58%
PAH-CHD 10%
PAH-CTD 29%
Other 3%*
NEARLY 1/2 OF ALL PATIENTS WERE FC II
WHO FC II 46%
FC I (0.8%) + FC IV (1%)
WHO FC III 53%
80% ON PAH BACKGROUND THERAPY
ERA + PDE5i33%
PDE5i 32%
ERA 15%
None 20%
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI® (selexipag). Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
*Other=drugs and toxins (2%) and HIV (1%).
6MWD=6-minute walk distance; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.
1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. doi:10.1183/13993003.01908-2018 3. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 4. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary hypertension. N Engl J Med. 2015;373:2522-2533 and suppl. 5. Data on file. Actelion Pharmaceuticals US, Inc. GRIPHON Baseline Characteristics Study Report.
